Israel: After moving into the race to vaccinate its population against coronaviruse, Israel has struck a deal with vaccine maker Pfizer, in exchange for its continued influx of hard-to-obtain vaccines, with the international drug giant providing vast amounts of medical data, the troop promises to share.
Supporters say the deal could allow Israel to become the first country to vaccinate most of its population while providing valuable research that could help the rest of the world. But critics say the deal raises significant ethical concerns, including potential privacy violations and deepening global divisions, enabling rich countries to impose vaccines as poor populations, including those in Israeli occupation Palestinians in the West Bank and Gaza, also have to wait a long time. Inoculated
Prime Minister Benjamin Netanyahu – who is leading the nation’s March elections as Israel’s Vaccinator-in-Chief – said earlier this month that he would accelerate the vaccine’s delivery to Israel as chief executive of Pfizers Arrived to deal with.
“Israel will be a global model state,” he said. Israel will share statistical data with Pfizer and the entire world to help develop a strategy to defeat coronavirus.
Israeli Health Minister Yuli Edelstein told that to see how the government “affects the data,” first, the level of disease in Israel, the possibility of opening up the economy, various aspects of social life, and whether there Will tell There is no effect of vaccination. ”
The Pfizer vaccine, developed with German partner BioNotech, has received emergency approval from the US Food and Drug Administration and the European Union’s regulatory agency and is believed to provide up to 95 percent protection against Kovid-19. But much is unknown, including its long-term safety and whether it can prevent the virus’s transmission.
Israel, home to approximately 9.3 million people, is considered an ideal place to study these questions. Four publicly funded HMOs provide mandatory universal health care with meticulous digital records. This centralized system has helped Israel deliver more than 2 million doses of the vaccine within a month. Israel has also bought modern and AstraZeneca vaccines.
The inoculation blitz is a matter of national pride. It is also at the center of the Netanyahu reunion campaign. It seeks to divert attention from its ongoing corruption trial, Israel’s deep economic crisis, and the latest virus surge.
The Ministry of Health has recorded more than 543,00 cases since the onset of the epidemic and around 4,000 deaths. Israeli officials say they aim to have vaccinations in most areas of the country by the end of March, around election day.
But even after a new version of the agreement was released between Israel and the Ministry of Health on Sunday, the exact pro-bid between Israel and Pfizer is unclear.
Neither Israel nor Pfizer would say how much Israel paid for vaccines, although Edelstein called it a “classical victory” for both sides. Israeli media has reported that Israel paid at least 50 percent more than other countries. The data is reportedly being shared with the World Health Organization, but the global body did not respond to repeated requests for comment.
Earlier this month, the WHO’s head appealed to drug makers and wealthy countries to “stop doing bilateral deals,” saying they widely influenced a U.N.-backed effort. Tedros Adhanom Ghebreyesus did not unite any countries or companies.
Last week, Drs. Siddharth Dutta, WHO Europes’ program manager for vaccine-preventive diseases and vaccination, said the agency is trying to collect “dissatisfied” data based on age, gender, local area, employment and other factors. Security issues are deployed in the form of vaccines.
Israel had already announced the acquisition of millions of vaccine doses before the announcement of the Pfizer deal. It is unclear how the volume or speed of delivery has changed or whether the vaccines have been removed from other countries.
This system has drawn attention to the uneven distribution of vaccines between rich and developing countries. A recent estimate by the International Rescue Committee states that only 20% of low-income countries in the world are likely to be vaccinated by the end of 2021 from the WHO’s global COVAX campaign.
“It’s a shady one, an under-deal that gives priority to some countries without any transparency,” said Lawrence Gostin, a professor of global health law at Georgetown University in Washington. “In the end, its low and middle-income countries will be left behind.”
The head of the School of Public Health at Ben Gurion University in Israel and advisor to the government on coronavirus policy, Drs. Nadav Davydiewicz said the deal has upset about the profound disparity in vaccination efforts.